Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Bayer HealthCare
Homme Max 99 ans
Bayer HealthCare Pharmaceuticals INC
MAJ Il y a 4 ans
Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A
To evaluate the effects of secondary prophylaxis on bleeding frequency (number of all bleeds per year) compared to episodic treatment.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
Proof of concept study to investigate the impact of BAY 58-2667 given intravenously in patients with acute decompensated chronic congestive heart failure
The primary objective of part A is to investigate the hemodynamic and subjective effects on dyspnoea and well-being of 3 doses of BAY 58-2667 given intravenously over 2 hours per dose step in a dose e...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
A randomized, explorative, double-blind, double-dummy, multi-center, parallel group study to assess sustainable efficacy of once daily vardenafil (10 mg) for 12 and 24 weeks versus vardenafil PRN in men with mild or mild to moderate erectile dysfunction
The objective of this study is to explore the prophylactic (prophylaxis of deterioration) or curative efficacy and safety of long-term (12 and 24 weeks) daily administration of vardenafil therapy (adm...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
Study to investigate safety, tolerability, pharmacodynamics and pharmacokinetic properties of BAY 63-2521 after dosing of a 2 mg tablet in 20 patients with Raynaud’s phenomenon (RP)
The primary objective of the study is to investigate the safety, tolerability and pharmacodynamics of a single oral dose of BAY 63-2521 administered in patients suffering from Raynaud’s phenomenon
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
Randomized, double-blind, placebo-controlled, parallel group study of vardenafil 10 mg twice daily to assess the effect on urodynamics in patients with Overactive Bladder (detrusor overactivity)
To determine the therapeutic effect of vardenafil on Overactive Bladder by means of urodynamic measurements (filling cystometry and pressure flow investigations). In addition, a micturition diary wil...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
Refametinib given to patients with unresectable or metastatic HCC carrying a RAS mutation
The primary objective is to evaluate the efficacy of refametinib in patients with KRAS or NRAS mutant unresectable or metastatic HCC.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus aspirin in the long-term prevention of blood clots from reccuring in the leg or lung
The primary efficacy objective is to evaluate whether rivaroxaban, in doses of 10 mg or 20 mg, is superior to acetylsalicylic acid (ASA) 100 mg in the prevention of the primary efficacy outcome (i.e. ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
Single-center, open-label, uncontrolled study to investigate the effects of the transdermal contraceptive patch containing 0.55 mg ethinylestradiol and 2.1 mg gestodene (material no. 80876395) on the endometrium in a 21-day regimen for 13 cycles in 80 healthy women
The primary objective of this study is to investigate the effect of the transdermal contraceptive patch (material no. 80876395, FC Patch Low containing 0.55 mg EE and 2.1 mg GSD) on the endometrium.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
A study investigating the efficacy and safety of copanlisib versus placebo inpatients with rituximab-refratory indolent non-Hodgkin's lymphoma. Copanlisib nell’iNHL di Fase III refrattario a rituximab
to investigate whether copanlisib as monotherapy is superior to placebo in prolonging progression-free survival (PFS) in patients with rituximab-refractory iNHL who have received two or more prior lin...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
A clinical trial investigating safety and efficacy of a long-acting factor VIII in severe hemophila A Studio clinico per valutare sicurezza ed efficacia di un fattore VIII a lunga emivita nell'emofilia A grave
• To assess the efficacy of BAY 94-9027 in prevention and treatment of bleeding at different infusion schedules Part B: Major surgery using BAY 94-9027 • To assess the safety and efficacy of BAY 94-...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
5
6
7
8
9
10
11
12
13
14
Suivant